INS and diabetes mellitus: Overall, the present real‐world study supports previous evidence from an RCT and a real‐world study with a matched controlled group that the digital device ESYSTA is associated with significant and continuous reductions in HbA1c levels in T1D and T2D insulin‐treated people with diabetes.